Ludwig, H.; Wilhelminen Cancer Research Institute, c/o 1st Department of Medicine, Center for Oncology, Hematology, and Palliative Care, Clinic Ottakring, Vienna, Austria
Boccadoro, M.; Myeloma Unit, Division of Hematology, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza, Torino, Italy
Moreau, Philippe; CIMA, IDISNA, CIBERONC, Clínica Universidad de Navarra, Pamplona, Spain
San-Miguel, J.; Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy
Cavo, M.; The Institute of Cancer Research, London, United Kingdom
Pawlyn, C.; Department of Hematology, Amsterdam UMC, VU University, Amsterdam, Netherlands
Zweegman, S.; Hôpital Claude Huriez, Lille University Hospital, Lille, France
Facon, T.; Department of Medical Oncology and Hematology, Cantonal Hospital St Gallen, St Gallen, Switzerland
Driessen, C.; Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
Hajek, R.; Hematology & Medical Oncology, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece
Dimopoulos, M. A.; Myeloma Unit, Division of Hematology, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza, Torino, Italy
Gay, F.; Unité de Génomique du Myélome, University of Toulouse, Toulouse, France
Avet-Loiseau, H.; Hematology & Medical Oncology, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece
Terpos, E.; 1st Department of Medicine, Center for Hematology, Oncology, and Palliatic Care, Clinic Ottakring, Vienna, Austria
Zojer, N.; Department of Clinical Hematology and Cellular Therapy, Hospital Saint-Antoine, Sorbonne University, Paris, France
Mohty, M.; IBSAL, Cancer Research Center, University Hospital of Salamanca, Salamanca, Spain
Mateos, M.-V.; Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany
Einsele, H.; Department of Hematology, UZ Leuven, Leuven, Belgium
Delforge, M.
Caers, Jo ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques
Weisel, K.
Jackson, G.; NCCC, Newcastle upon Tyne Hospitals Trust, Newcastle upon Tyne, United Kingdom
Garderet, L.; INSERM, UMR_S 938, Centre de Recherche Saint-Antoine-Team Proliferation and Differentiation of Stem Cells, Assistance Publique-Hôpitaux de Paris, Hôpital Pitié Salpêtrière, Service d’Hématologie, Sorbonne Université, Paris, France
Engelhardt, M.; Interdisciplinary Tumor Center, Faculty of Freiburg, University of Freiburg, Freiburg, Germany
van de Donk, N.; Department of Hematology, Amsterdam UMC, VU University, Amsterdam, Netherlands
Leleu, X.; Poitiers University Hospital, Poitiers, France
Goldschmidt, H.; Internal Medicine V and National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany
Beksac, M.; Department of Hematology, Ankara University, Ankara, Turkey
Nijhof, I.; Department of Hematology, Amsterdam UMC, VU University, Amsterdam, Netherlands
Abildgaard, N.; Department of Hematology, Odense University Hospital, University of Southern Denmark, Odense, Denmark
Bringhen, S.; Myeloma Unit, Division of Hematology, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza, Torino, Italy
Sonneveld, P.; Erasmus MC Cancer Institute, Erasmus University of Rotterdam, Rotterdam, Netherlands
Alemu A, Singh M, Blumberg C, Richards JO, Oaks MK, Thompson MA. Multiple myeloma vaccination patterns in a large health system: a pilot study. J Patient Cent Res Rev. 2017;4:53–9.
Brioli A, Klaus M, Sayer H, Scholl S, Ernst T, Hilgendorf I, et al. The risk of infections in multiple myeloma before and after the advent of novel agents: a 12-year survey. Ann Hematol. 2019;98:713–22.
Kristinsson SY, Tang M, Pfeiffer RM, Bjorkholm M, Goldin LR, Blimark C, et al. Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study. Haematologica. 2012;97:854–8.
Blimark C, Holmberg E, Mellqvist UH, Landgren O, Bjorkholm M, Hultcrantz M, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100:107–13.
National Center for Immunization and Respiratory Diseases, General Best Practice Guidelines for Immunization: Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP): Altered Immunocompetence. 2019. https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.html. Accessed 1 Mar 2020.
World Health Organisation: Vaccines and Immunization; recommendations for routine immunization. 2019. https://www.who.int/immunization/policy/immunization_tables/en/. Accessed 1 Mar 2020.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in OncologyTM. Prevention and Treatment of Cancer-Related Infections. 2020. https://www.nccn.org/professionals/physician_gls/pdf/infections.pdf. Accessed 1 Mar 2020.
Rieger CT, Liss B, Mellinghoff S, Buchheidt D, Cornely OA, Egerer G, et al. Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors-Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). Ann Oncol. 2018;29:1354–65.
Khan AR, Khan S, Zimmerman V, Baddour LM, Tleyjeh IM. Quality and strength of evidence of the Infectious Diseases Society of America clinical practice guidelines. Clin Infect Dis. 2010;51:1147–56.
Karlsson J, Andreasson B, Kondori N, Erman E, Riesbeck K, Hogevik H, et al. Comparative study of immune status to infectious agents in elderly patients with multiple myeloma, Waldenstrom’s macroglobulinemia, and monoclonal gammopathy of undetermined significance. Clin Vaccine Immunol. 2011;18:969–77.
Sasaki S, Sullivan M, Narvaez CF, Holmes TH, Furman D, Zheng NY, et al. Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies. J Clin Investig. 2011;121:3109–19.
Murasko DM, Bernstein ED, Gardner EM, Gross P, Munk G, Dran S, et al. Role of humoral and cell-mediated immunity in protection from influenza disease after immunization of healthy elderly. Exp Gerontol. 2002;37:427–39.
Iuliano AD, Roguski KM, Chang HH, Muscatello DJ, Palekar R, Tempia S, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2018;391:1285–300.
Suzuki Y. Sialobiology of influenza: molecular mechanism of host range variation of influenza viruses. Biol Pharm Bull. 2005;28:399–408.
Chen YQ, Wohlbold TJ, Zheng NY, Huang M, Huang Y, Neu KE, et al. Influenza infection in humans induces broadly cross-reactive and protective neuraminidase-reactive antibodies. Cell. 2018;173:417–29.e410.
Krammer F, Fouchier RAM, Eichelberger MC, Webby RJ, Shaw-Saliba K, Wan H, et al. NAction! How can neuraminidase-based immunity contribute to better influenza virus vaccines? mBio. 2018;9:e02332–17.
Devarajan P, Bautista B, Vong AM, McKinstry KK, Strutt TM, Swain SL. New insights into the generation of CD4 memory may shape future vaccine strategies for influenza. Front Immunol. 2016;7:136.
Nordoy T, Aaberge IS, Husebekk A, Samdal HH, Steinert S, Melby H, et al. Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae. Med Oncol. 2002;19:71–8.
Pollyea DA, Brown JM, Horning SJ. Utility of influenza vaccination for oncology patients. J Clin Oncol. 2010;28:2481–90.
Bitterman R, Eliakim-Raz N, Vinograd I, Zalmanovici Trestioreanu A, Leibovici L, Paul M. Influenza vaccines in immunosuppressed adults with cancer. Cochrane Database Syst Rev. 2018;2:Cd008983.
Robertson JD, Nagesh K, Jowitt SN, Dougal M, Anderson H, Mutton K, et al. Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma. Br J Cancer. 2000;82:1261–5.
Sanada Y, Yakushijin K, Nomura T, Chayahara N, Toyoda M, Minami Y, et al. A prospective study on the efficacy of two-dose influenza vaccinations in cancer patients receiving chemotherapy. Jpn J Clin Oncol. 2016;46:448–52.
Hahn M, Schnitzler P, Schweiger B, Kunz C, Ho AD, Goldschmidt H, et al. Efficacy of single versus boost vaccination against influenza virus in patients with multiple myeloma. Haematologica. 2015;100:e285–8.
Branagan AR, Duffy E, Albrecht RA, Cooper DL, Seropian S, Parker TL, et al. Clinical and serologic responses after a two-dose series of high-dose influenza vaccine in plasma cell disorders: a prospective, single-arm trial. Clin Lymphoma Myeloma Leuk. 2017;17:296–304.e292.
de Lavallade H, Garland P, Sekine T, Hoschler K, Marin D, Stringaris K, et al. Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host. Haematologica. 2011;96:307–14.
Dolan GP, Harris RC, Clarkson M, Sokal R, Morgan G, Mukaigawara M, et al. Vaccination of healthcare workers to protect patients at increased risk of acute respiratory disease: summary of a systematic review. Influenza Other Respir Viruses. 2013;7 Suppl 2: 93–6.
World Health Organization, Geneva 2019: Global influenza strategy 2019–2030. https://www.who.int/influenza/global_influenza_strategy_2019_2030/en/. Accessed 27 Nov 2019.
Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases (NCIRD). 2019. https://www.cdc.gov/flu/prevent/vaccinations.htm. Accessed 27 Nov 2019.
Referenced with permission from the NCCN Guidelines for Prevention and Treatment of Cancer-Related Infections V.1.2020. National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed 4 Mar 2020. www.NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
World Health Organisation: Recommendations for routine immunization - summary tables, table 4. 2019. https://www.who.int/immunization/policy/Immunization_routine_table4_FR.pdf?ua=1. Accessed 28 Feb 2020.
Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases (NCIRD). 2016. https://www.cdc.gov/vaccines/adults/rec-vac/hcw.html. Accessed 28 Feb 2020.
Maltezou HC, Poland GA. Immunization of health-care providers: necessity and public health policies. Healthcare. 2016;4:47.
Alemu A, Richards JO, Oaks MK, Thompson MA. Vaccination in multiple myeloma: review of current literature. Clin Lymphoma Myeloma Leuk. 2016;16:495–502.
Drgona L, Gudiol C, Lanini S, Salzberger B, Ippolito G, Mikulska M. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4). Clin Microbiol Infect. 2018;24:S83–94.
Schmader K. Herpes zoster. Clin Geriatr Med. 2016;32:539–53.
Pandit A, Leblebjian H, Hammond SP, Laubach JP, Richardson PG, Baden LR, et al. Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation. Bone Marrow Transplant. 2018;53:942–5.
Winston DJ, Mullane KM, Cornely OA, Boeckh MJ, Brown JW, Pergam SA, et al. Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391:2116–27.
Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Diez-Domingo J, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375:1019–32.
Dagnew AF, Ilhan O, Lee WS, Woszczyk D, Kwak JY, Bowcock S, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. Lancet Infect Dis. 2019;19:988–1000.
Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, Department of Health and Human Services. Vaccine Information Statement (Interim), Hepatitis A Vaccine (7/28/2020), 42 U.S.C. § 300aa-26. https://www.cdc.gov/vaccines/hcp/vis/vis-statements/hep-a.html. Accessed 28 Jul 2020.
Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560–99.
Lee S, Kim HW, Kim KH. Antibodies against hepatitis A and hepatitis B virus in intravenous immunoglobulin products. J Korean Med Sci. 2016;31:1937–42.
Hwang JP, Somerfield MR, Alston-Johnson DE, Cryer DR, Feld JJ, Kramer BS, et al. Hepatitis B virus screening for patients with cancer before therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update. J Clin Oncol. 2015;33:2212–20.
Lampertico P, Agarwal K, Berg T, Buti M, Janssen HLA, Papatheodoridis G, et al. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370–98.
Sarmati L, Andreoni M, Antonelli G, Arcese W, Bruno R, Coppola N, et al. Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation-a position paper. Clin Microbiol Infect. 2017;23:935–40.
Duncan JD, Urbanowicz RA, Tarr AW, Ball JK. Hepatitis C virus vaccine: challenges and prospects. Vaccines. 2020;8:1–23.
Kontio M, Jokinen S, Paunio M, Peltola H, Davidkin I. Waning antibody levels and avidity: implications for MMR vaccine-induced protection. J Infect Dis. 2012;206:1542–8.
Ljungman P, Lewensohn-Fuchs I, Hammarstrom V, Aschan J, Brandt L, Bolme P, et al. Long-term immunity to measles, mumps, and rubella after allogeneic bone marrow transplantation. Blood. 1994;84:657–63.
Ljungman P, Cordonnier C, Einsele H, Englund J, Machado CM, Storek J, et al. Vaccination of hematopoietic cell transplant recipients. Bone Marrow Transplant. 2009;44:521–6.
Simell B, Lahdenkari M, Reunanen A, Kayhty H, Vakevainen M. Effects of ageing and gender on naturally acquired antibodies to pneumococcal capsular polysaccharides and virulence-associated proteins. Clin Vaccin Immunol. 2008;15:1391–7.
Geno KA, Gilbert GL, Song JY, Skovsted IC, Klugman KP, Jones C, et al. Pneumococcal capsules and their types: past, present, and future. Clin Microbiol Rev. 2015;28:871–99.
Bahuaud M, Bodilis H, Malphettes M, Maugard Landre A, Matondo C, Bouscary D, et al. Immunogenicity and persistence of the 13-valent pneumococcal conjugate vaccine (PCV13) in patients with untreated smoldering multiple myeloma (SMM): a pilot study. Heliyon. 2017;3:e00441.
Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372:1114–25.
Hinge M, Ingels HA, Slotved HC, Molle I. Serologic response to a 23-valent pneumococcal vaccine administered prior to autologous stem cell transplantation in patients with multiple myeloma. APMIS. 2012;120:935–40.
Mustafa SS, Shah D, Bress J, Jamshed S. Response to PCV13 vaccination in patients with multiple myeloma versus healthy controls. Hum Vaccines Immunother. 2019;15:452–4.
Pasiarski M, Sosnowska-Pasiarska B, Grywalska E, Stelmach-Goldys A, Kowalik A, Gozdz S, et al. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in patients with monoclonal gammopathy of undetermined significance—relationship with selected immune and clinical parameters. Clin Interv Aging. 2019;14:1741–9.
Karlsson J, Roalfe L, Hogevik H, Zancolli M, Andreasson B, Goldblatt D, et al. Poor correlation between pneumococcal IgG and IgM titers and opsonophagocytic activity in vaccinated patients with multiple myeloma and Waldenstrom’s macroglobulinemia. Clin Vaccin Immunol. 2016;23:379–85.
Lode H, Schmoele-Thoma B, Gruber W, Ahlers N, Fernsten P, Baker S, et al. Dose-ranging study of a single injection of pneumococcal conjugate vaccine (1 x, 2 x, or 4 x) in healthy subjects aged 70 years or older. Vaccine. 2011;29:4940–6.
Harboe ZB, Dalby T, Weinberger DM, Benfield T, Molbak K, Slotved HC, et al. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis. 2014;59:1066–73.
Andrews NJ, Waight PA, George RC, Slack MP, Miller E. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine. 2012;30:6802–8.
High NJ, Fan F, Schwartzman JD. Chapter 97—haemophilus influenzae. Molecular medical microbiology, 2nd ed. vol. 3. Amsterdam: Academic Press; 2015. pp 1709–28.
Nix EB, Hawdon N, Gravelle S, Biman B, Brigden M, Malik S, et al. Risk of invasive Haemophilus influenzae type b (Hib) disease in adults with secondary immunodeficiency in the post-Hib vaccine era. Clin Vaccine Immunol. 2012;19:766–71.
Palazzo M, Shah GL, Copelan O, Seier K, Devlin SM, Maloy M, et al. Revaccination after autologous hematopoietic stem cell transplantation is safe and effective in patients with multiple myeloma receiving lenalidomide maintenance. Biol Blood Marrow Transplant. 2018;24:871–6.
Feldman C, Anderson R. Meningococcal pneumonia: a review. Pneumonia. 2019;11:3.
Bennett DE, Meyler KL, Cafferkey MT, Cunney RJ. Diversity of meningococci associated with invasive meningococcal disease in the Republic of Ireland over a 19 year period, 1996–2015. PloS ONE. 2020;15:e0228629.
Kristinsson SY, Gridley G, Hoover RN, Check D, Landgren O. Long-term risks after splenectomy among 8,149 cancer-free American veterans: a cohort study with up to 27 years follow-up. Haematologica. 2014;99:392–8.
Einarsdottir S, Ljungman P, Kaijser B, Nicklasson M, Horal P, Norder H, et al. Humoral immunity to tetanus, diphtheria and polio in adults after treatment for hematological malignancies. Vaccine. 2020;38:1084–8.
Ljungman P, Wiklund-Hammarsten M, Duraj V, Hammarstrom L, Lonnqvist B, Paulin T, et al. Response to tetanus toxoid immunization after allogeneic bone marrow transplantation. J Infect Dis. 1990;162:496–500.
Parkkali T, Ruutu T, Stenvik M, Kuronen T, Kayhty H, Hovi T, et al. Loss of protective immunity to polio, diphtheria and Haemophilus influenzae type b after allogeneic bone marrow transplantation. APMIS. 1996;104:383–8.
Suzuki N, Mizue N, Hori T, Hatakeyama N, Kudoh T, Tsutsumi H. Pertussis in adolescence after unrelated cord blood transplantation. Bone Marrow Transplant. 2003;32:967.
Nordoy T, Husebekk A, Aaberge IS, Jenum PA, Samdal HH, Flugsrud LB, et al. Humoral immunity to viral and bacterial antigens in lymphoma patients 4-10 years after high-dose therapy with ABMT. Serological responses to revaccinations according to EBMT guidelines. Bone Marrow Transplant. 2001;28:681–7.
Renaud L, Schraen S, Fouquet G, Guidez S, Demarquette H, Nudel M, et al. Response to pneumococcal vaccination in multiple myeloma. Cancer Med. 2019;8:3822–30.
Cordonnier C, Einarsdottir S, Cesaro S, Di Blasi R, Mikulska M, Rieger C, et al. Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019;19:e200–12.
Inazawa N, Hori T, Nojima M, Saito M, Igarashi K, Yamamoto M, et al. Virus reactivations after autologous hematopoietic stem cell transplantation detected by multiplex PCR assay. J Med Virol. 2017;89:358–62.
Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58:309–18.
Gueller S, Allwinn R, Mousset S, Martin H, Wieters I, Herrmann E, et al. Enhanced immune response after a second dose of an AS03-adjuvanted H1N1 influenza A vaccine in patients after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011;17:1546–50.
Cordonnier C, Labopin M, Chesnel V, Ribaud P, De La Camara R, Martino R, et al. Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation. Clin Infect Dis. 2009;48:1392–401.
Frerichs KA, Bosman PWC, Nijhof IS, Zweegman S, van de Donk N. Cytomegalovirus reactivation in a patient with extensively pretreated multiple myeloma during daratumumab treatment. Clin Lymphoma Myeloma Leuk. 2019;19:e9–11.
Hartkamp A, Mulder AH, Rijkers GT, van Velzen-Blad H, Biesma DH. Antibody responses to pneumococcal and haemophilus vaccinations in patients with B-cell chronic lymphocytic leukaemia. Vaccine. 2001;19:1671–7.
Noonan K, Rudraraju L, Ferguson A, Emerling A, Pasetti MF, Huff CA, et al. Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses. Clin Cancer Res. 2012;18:1426–34.
Maltezou HC, Poland GA. Immunization of healthcare personnel in Europe: time to move forward with a common program. Vaccine. 2020;8:3187–90.
Government of Canada. Immunization of workers: Canadian Immunization Guide for Health Professionals. 2019. https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-11-immunization-workers.html#p3c10t1. Accessed 31 Mar 2020.
U.S. Department of Health and Human Services (HHS), Office of Infectious Disease and HIV/AIDS Policy. 2020. https://www.vaccines.gov/basics/safety/side_effects. Accessed 29 Feb 2020.
Plotkin SA, Offit PA, DeStefano F, Larson HJ, Arora NK, Zuber PLF, et al. The science of vaccine safety: summary of meeting at Wellcome Trust. Vaccine. 2020;38:1869–80.
